Antibody | Epitope | Cross Reactivity | Ref |
---|---|---|---|
4G8 | Raised against synthetic peptide Aβ17-24; epitope lies within aa 18–23; recognises multiple forms of Aβ | Cross reacts with APP770 and P3; reacts with conformational epitope of aggregated fibrils including α-synuclein | |
6E10 | Raised against Aβ1-17; epitope lies within aa 4–9; recognises Aβ with intact N-terminal epitope | Cross reacts with APP and Aβ(1–16); No reaction predicted with P3 | |
6F3D | Raised against synthetic peptide Aβ8-17; epitope lies within aa 10–15; recognises Aβ with intact N-terminal epitope | Predicted to react with Aβ(1–16); Does not react with P3 | |
MBC40 (Aβ40) | Recognises C-terminal Aβ peptides ending at aa40; epitope not well described | Cross reacts with N-terminal truncated peptides including P3 | [2] |
MBC42 (Aβ42) | Recognises C-terminal Aβ peptides ending at aa42; epitope not well described | Cross reacts with N-terminal truncated peptides including P3 | [2] |
BS85 | Raised against Aβ(25–35); recognises Aβ38, Aβ39, Aβ40, Aβ42 and Aβ43; epitope not well described | Cross reacts with N-terminal truncated peptides including P3 | [2] |
BC05 | Raised against Aβ(35–43); recognises Aβ42 and Aβ43; epitope not well described | Cross reacts with N-terminal truncated peptides including P3; does not recognise Aβ40; used in commercial ELISA kits for the detection of Aβ42 | |
BA27 | Raised against Aβ(1–40) Recognises Aβ40; 100-1000x more reactive with Aβ40 than Aβ42 and Aβ43; epitope not well described | Cross reacts with N-terminal truncated peptides including P3; used in commercial ELISA kits for the detection of Aβ40 | [7] |
AβN17 (Leu) | Raised against P3(40); recognises P3(40) and synthetic P3(42) peptide; epitope not well described | Reactivity with insoluble, aggregated P3(42) not confirmed | |
3D6 | Raised against Aβ with N-terminal aspartic acid; epitope lies within aa 1–5; recognises multiple C-terminal variations | Does not cross react with sAPPs or full length APP; No reactivity with N-terminally altered Aβ; No reaction predicted with P3; parent of Bapineuzumab | |
266 | Raised against synthetic Aβ; epitope lies within aa 13–28; recognises soluble monomer and multiple C-terminal variations | Cross reacts with various plasma proteins containing the core sequence KLVFF; does not cross react with P3; parent of Solanezumab |